[CDK inhibitors for therapy of cancer].
Nishio
K
K
Pharmacology Division, National Cancer Center Research Institute.
D000470:Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000378:metabolism; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D016213:Cyclins / Q000502:physiology; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D021381:Protein Transport; D019311:Staurosporine / Q000031:analogs & derivatives; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000470:Alkaloids; D018797:Cell Cycle Proteins; D016213:Cyclins; D005419:Flavonoids; D010880:Piperidines; C077990:alvocidib; C054852:7-hydroxystaurosporine; D018844:Cyclin-Dependent Kinases; D019311:Staurosporine